Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Might be why they are taking action to protect the BOD jobs and to discourage hostile takeover attempts, possible approval sooner than they expected? Astra might be a hostile agent at that time if it happened.
Just a thought but we found out about the presentation next Tuesday about three months ago so is it out of the realm of possibilities that the company had already gone about doing the necessary filings in Europe to get approval and now have approval in hand and will announce it this week? The filings Friday night looked very protective and sounded as though no immediate dilution will take place. Perhaps they announce approval, let the share price run a bit and when appropriate cut a deal? That would be the responsible thing to do.
Could that be to prevent a hostile takeover attempt in the event the GOG P2 has had some interesting events occur?
They'll it was created by shorts covering when in fact it was the big players who were short and they already had the shares to cover. The key is all the big Pharmas need their piece of ADXS.
Once all the big players are in, they turn the Algos in the opposite direction and create a PUMA situation. Probably a couple deals down the road in my opinion.
Ah, Merck will sign a deal with ADXS after Astra.
If there are still retail shorts, well they deserve to part ways with their money and I won't feel bad for them for one second!
Gotcha
Those short shares aren't retail, JMO for what it's worth. Those short shares are nothing more than a excuse for the HFT manipulators to point to and say that's the reason the share price is down here, it's not us. It gives them an out if they get caught. I think they already have the short covered if needed. I'll also bet the shares short doesn't move much at all FBG.
I'll be parting ways with a substantial portion of my investment at twenty, you have to know Merck is up after that and they won't want to pay any more than Amgen or Astra for their 10 percent of the company. Trade it like you hate it! It's the only way to prevent getting diluted into oblivion!
My concern is exactly how many big pharmas do we have waiting in the wings waiting to do deals and how many of them can pay an investment bank to HFT the share price right back down to nine bucks until Dan gives a portion of the company for peanuts?
I'd say Merck is after Astra and I might do something I haven't done before, unload everything on a pop close to twenty!
I'm sure if we get EU approval, We could take our pick of potential partners, probably on who would pay up for millions of shares, not manipulate LTSH into oblivion.
Why not just do a deal with someone altogether different if this is how they want to play?
I agree
You know it doesn't scream that Advaxis is in the drivers seat if we can't get at least what fidelity paid after the Amgen deal for the company's shares. This is why we can't break from the HFT because Dan continually Hands out shares in deals for a hugely discounted SP IMO.
Hopefully we get a big milestone payment from Amgen and won't need to just give away a chunk of the company, after all if we are doing a deal for cervical in the EU, aren't we doing them a favor?
I trade for my girls and teach them as I go. Yes they are 100% invested in Advaxis!
Self directed college savings account thorough your broker with you as the custodian.
Nothing other than HFT. We've only had great news with a lot of new hiring. LTSH are used to it.
Don't forget the PETX deal comes with significant milestone payments itself!
I bought 5000 more
Only one kind of trade I'm interested in and it's the same one I've been making since 2008! I'll keep buying and holding onto every share that I buy! If that makes tough on some with other aspirations, well good because I have reasons for being here that are my own, ha ha!
Nobody is expecting aha data next week, I think we could see aha data!
How long have people been saying over a hundred in one, two or three years. We're worth that now. I've been invested here almost a decade and I'll say it right now, It's going to take an event, an aha moment that pulls in an overwhelming amount of investors to stop the HFT manipulation.
I hope the conference coming up shows that more doses promotes epitope seeding that continues once dosing stops allowing for at the very least stable disease and probably more. I truly think there will be aha data garnered from the long term GOG data just at there was good data obtained from the HER2 dog study.
Good luck fellow longs, hang tough and relax!
I can weight these guys out, they want to keep their shares and cover their short with yours. It'll be a cold day in hell before they cover with mine and as a matter of I might want some of your shares too, ha ha!
Probably spot on.
Probably someone on the short side with butt cheeks clenched at their keyboard having a Vagal response to the stress of nobody selling into the shenanigans the last couple of weeks!
I hope it bankrupts them in the process, ha ha!
Sure it does if your short and are crapping yourself trying to figure out how to pry shares loose to do it. They are using HFT to try and scare the traders out.
Dang, I knew I misspelled that, dang it any how. Thx for the correction!
Would not surprise me at all to see 10Q tomorrow with milestone payment included. The action today gives me confidence it is probably eminent.
So, If there was a milestone payment for the IND acceptance by the FDA, would posters here expect to see it in this 10q or the next?
Most of the ones I've seen were required to run P3 but were allowed to market their product while running P3.
Most likely the investment banker brokering the deal. It's probably a little late to worry at this point.
I think the company would keep the anal cancer indication.
I was originally thinking that there would be a combo deal for end stage metastatic disease with AstraZeneca. As the company said they expect to start a second P3 for this indication. The combo p2 study with Astra is far enough along that a deal could be signed for the US and EU. Advaxis could keep the indication with our vaccine being used as an adjuvant. The deal might include head and beck as well as there is also a combo study for that indication as well.
I'd say maybe better than 50/50 given the data they've garnered and it may look even better long term with patients getting 3 or more doses. It'll be interesting to see what data they give us at the conference coming up.
Also son forget they brought in the gentleman who has experience with EU approval.
Makes sense to me FBG!
I like it James!
Depends on how much of the construct they make a deal on. We have a deal maker now, I'm sure she knows what it should be worth.
Yeah, Nine would be above my recent buy price I guess.